Uveitis - Global Drug Forecast and Market Analysis to 2029

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $10,995	203 Pages	GlobalData	June, 2021	GBDT16704757

Best Price Guarantee
Price	from $10,995
Length	203 Pages
Publisher	GlobalData
Published Date	June, 2021
SKU	GBDT16704757

Uveitis - Global Drug Forecast and Market Analysis to 2029

Summary

Uveitis affecting the anterior chamber is typically treated with corticosteroid eye drops such as Allergan’s Pred Forte (prednisolone acetate) or Novartis’ Maxidex (dexamethasone). Inflammation that involves other parts of the uveal tract can be treated with injectable corticosteroids such as Novartis’ Triesence (triamcinolone acetonide) or ocular implants such as Allergan’s Ozurdex (dexamethasone).

When the disease is caused by an autoimmune disorder, immunomodulators such as methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine can be used to manage patients.

AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab) are monoclonal antibodies that are injected periodically to manage uveitis that is associated with indications such as rheumatoid arthritis and ulcerative colitis.

GlobalData projects the global non-infectious uveitis marketplace-which, for the purposes of this report, comprises the nine major pharmaceutical markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Canada, and Australia)-to experience modest growth during the forecast period. The non-infectious uveitis market was valued at $286.3M in 2019. Growth in the market will be driven by the highly anticipated arrivals of intraocular drugs including an anti-inflammatory gene therapy, and a complement inhibitor. In 2029, the market is projected to reach $789.7M. The non-infectious uveitis market will expand at a Compound Annual Growth Rate (CAGR) of 10.7%.

Key Highlights

Drugs for non-infectious uveitis generated an estimated $286.3M in 2019, across the 9MM. GlobalData projects that the market will expand at a Compound Annual Growth Rate (CAGR) of 10.7%, reaching $789.7M in 2029.
Corticosteroids and immunosuppressants such as methotrexate, azathioprine, and tacrolimus are frequently used to treat patients with uveitis. The main issue with corticosteroids is their potential to cause elevated intraocular pressures and cataracts. Most patients develop these complications after long-term treatment with steroids.
Immunosuppressants such as azathioprine and tacrolimus take several weeks to bring about therapeutic outcomes. Humira (adalimumab) was the first biologic to gain approval for the treatment of uveitis. However, the drug is injected subcutaneously, and this has been linked to dermatological side effects and discomfort.
Anterior uveitis makes up the majority of diagnosed prevalent cases of the disease. However, symptoms can overlap with conjunctivitis and keratitis. This can lead to misdiagnosis and delayed initiation of effective treatment.
A number of drugs that are being developed for uveitis are also in the pipeline for other inflammatory diseases. This is useful because a significant percentage of patients with non-infectious uveitis also have an immune system-related comorbidity.
Factors that will contribute to growth in the market include continued use of AbbVie’s Humira for the treatment of both anterior and posterior uveitis, the introduction of non-steroidal therapies for the management of patients with anterior uveitis, and the assumed increase in the number of people who develop recurrent uveitis in line with the growing prevalence of autoimmune conditions.
Barriers to growth include the use of inexpensive generic formulations of immunosuppressants in all of the 9MM and lack of compliance among patients who are instructed to apply eye drops up to six times per day.
The top-selling late-stage pipeline agent in 2029 will be EYS-606. This is because the drug is expected to be the only gene therapy that will become available to treat anterior uveitis during the forecast window.

Key Questions Answered in This Report

What were the market leading drugs for uveitis in 2019?
When will the late-stage pipeline products launch in each of the 9MM?
What are the major clinical and environmental unmet needs in the uveitis market?
What are the key commercial opportunities for pharmaceutical companies developing therapies for uveitis?

Scope

Overview of epidemiological data, including information about disease duration (acute, chronic, recurrent), localization (anterior, intermediate, posterior, or panuveitis), and etiology (non-infectious, infectious, or idiopathic).
Examination of pathophysiology, symptoms, diagnosis, and disease management.
Annualized forecast of sales of uveitis therapeutics in the 9MM.
Examination of unmet needs, ongoing clinical trials, and profiles of individual marketed drugs.
Assessment of pipeline drugs, including clinical and commercial aspects of each therapy in development for the treatment of uveitis in adults.
Review of key market drivers and barriers.
Discussion of market potential and opportunities for drug developers in the uveitis space.

Reasons to Buy

The report will enable you to -

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the uveitis therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the uveitis therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

1 Uveitis: Executive Summary: 1.1 The Uveitis Market Will Almost Triple In Size from 2019-2029; 1.2 Steroid-Sparing Immunosuppressive Strategies Increasingly Favored by Clinicians and Patients; 1.3 Lack of Novel Therapies for Anterior Uveitis Will Limit Market Growth in Japan, Canada, and Australia; 1.4 Strategic Alliances Are a Key Priority for Drug Developers in This Therapy Area; 1.5 Focus Is On Label Expansion and Treatment of Comorbidities in the Uveitis Pipeline; 1.6 What Do Physicians Think?
2 Introduction: 2.1 Catalyst; 2.2 Related Reports; 2.3 Upcoming Reports
3 Disease Overview: 3.1 Etiology and Pathophysiology; 3.1.1 Overview; 3.1.2 Etiology; 3.1.3 Pathophysiology; 3.2 Classification or Staging Systems; 3.3 Prognosis and Quality of Life
4 Epidemiology: 4.1 Disease Background; 4.2 Risk Factors and Comorbidities; 4.3 Global and Historical Trends; 4.4 9MM Forecast Methodology; 4.4.1 Sources; 4.4.2 Forecast Assumptions and Methods; 4.4.3 Forecast Assumptions and Methods: Diagnosed Incident and Diagnosed Prevalent Cases of Uveitis - 9MM; 4.4.4 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation; 4.4.5 Diagnosed Prevalent Cases of Uveitis by Etiology; 4.4.6 Diagnosed Prevalent Cases of Uveitis by Severity; 4.4.7 Diagnosed Prevalent Cases of Uveitis by Laterality; 4.5 Epidemiological Forecast for Uveitis; 4.5.1 Diagnosed Incident Cases of Uveitis; 4.5.2 Age-Specific Diagnosed Incident Cases of Uveitis; 4.5.3 Sex-Specific Diagnosed Incident Cases of Uveitis; 4.5.4 Diagnosed Prevalent Cases of Uveitis; 4.5.5 Age-Specific Diagnosed Prevalent Cases of Uveitis; 4.5.6 Sex-Specific Diagnosed Prevalent Cases of Uveitis; 4.5.7 Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation, Etiology, and Severity; 4.5.8 Diagnosed Prevalent Cases of Uveitis by Laterality; 4.6 Discussion; 4.6.1 Epidemiological Forecast Insight; 4.6.2 COVID-19 Impact; 4.6.3 Limitations of Analysis; 4.6.4 Strengths of the Analysis
5 Disease Management: 5.1 Diagnosis and Treatment Overview; 5.2 Treatment Guidelines; 5.3 Pharmacotherapeutic Management of Non-infectious Uveitis; 5.3.1 Anterior Uveitis; 5.3.2 Intermediate, Posterior, and Panuveitis; 5.4 Marketed Drugs by Therapeutic Class; 5.4.1 Corticosteroids; 5.4.2 Immunosuppressants; 5.4.3 Antimuscarinic Agents; 5.5 Treatment of Uveitis by Geographic Region; 5.5.1 North America; 5.5.2 5EU; 5.5.3 Asia-Pacific; 5.6 KOL Insights on Disease Management
6 Competitive Assessment: 6.1 Overview
7 Unmet Needs and Opportunity Assessment: 7.1 Overview; 7.2 Increasing Disease Awareness Among Physicians and Patients; 7.3 Improving the Safety and Side-Effect Profiles of Pharmaceutical Products; 7.4 Making Drug Administration More Manageable for Patients; 7.5 Standardization of Treatment Guidelines for Different Disease Subtypes
8 R&D Strategies: 8.1 Overview; 8.1.1 Innovation in the Uveitis Pipeline; 8.1.2 Repurposing Biologic Therapies Marketed for Autoimmune Diseases; 8.1.3 Optimizing Administration of Immunosuppressants; 8.2 Clinical Trials Design; 8.2.1 Primary and Secondary Endpoints; 8.2.2 Trial Duration and Steroid-Sparing Treatment Strategies; 8.2.3 Uveitis as an Add-On Indication
9 Pipeline Assessment: 9.1 Overview; 9.2 Clinical Trials; 9.3 Late-Stage Pipeline Products; 9.4 Other Drugs in Clinical Development
10 Pipeline Valuation Analysis: 10.1 Overview; 10.2 Clinical Benchmarking; 10.3 Commercial Benchmarking; 10.4 Competitive Assessment
11 Current and Future Players: 11.1 Overview; 11.2 Trends in Corporate Strategy; 11.3 Deal-Making Trends; 11.4 Analysis of Company Portfolios in the Uveitis Market; 11.4.1 AbbVie and Allergan; 11.4.2 Novartis/Alcon; 11.5 Analysis of Company Portfolios in the Uveitis Pipeline; 11.5.1 Chugai; 11.5.2 Aciont; 11.5.3 Oculis; 11.5.4 Tarsius Pharma; 11.5.5 Enzo Biochem; 11.5.6 Santen; 11.5.7 Eyevensys; 11.5.8 Panoptes Pharma
12 Market Outlook: 12.1 Global Markets; 12.1.1 Forecast; 12.1.2 Drivers and Barriers - Global Issues; 12.2 US; 12.2.1 Forecast; 12.2.2 Key Events; 12.2.3 Drivers and Barriers; 12.3 5EU; 12.3.1 Forecast; 12.3.2 Key Events; 12.3.3 Drivers and Barriers; 12.4 Japan; 12.4.1 Forecast; 12.4.2 Key Events; 12.4.3 Drivers and Barriers; 12.5 Canada; 12.5.1 Forecast; 12.5.2 Key Events; 12.5.3 Drivers and Barriers; 12.6 Australia; 12.6.1 Forecast; 12.6.2 Key Events; 12.6.3 Drivers and Barriers
13 Appendix: 13.1 Bibliography; 13.2 Abbreviations; 13.3 Methodology; 13.3.1 Forecasting Methodology; 13.3.2 Diagnosed Patients; 13.3.3 Percent Drug-Treated Patients; 13.3.4 Drugs Included in Each Therapeutic Class; 13.3.5 Clinical Positioning of Marketed Drugs; 13.3.6 Clinical Positioning of Pipeline Drugs; 13.3.7 General Pricing Assumptions; 13.3.8 Pricing of Pipeline Agents; 13.4 Primary Research - KOLs Interviewed for This Report; 13.4.1 KOLs; 13.5 Primary Research - Prescriber Survey; 13.6 About the Authors; 13.6.1 Analyst; 13.6.2 Therapy Area Director; 13.6.3 Epidemiologist; 13.6.4 Managing Epidemiologist; 13.6.5 Global Director of Therapy Analysis and Epidemiology; 13.6.6 Global Head and EVP of Healthcare Operations and Strategy; 13.7 Contact Us
List of Tables: Table 1: Non-infectious Uveitis: Key Metrics in the 9MM; Table 2: SUN Working Group Anatomical Classification of Uveitis; Table 3: SUN Working Group Classification of Uveitis by Disease Onset and Duration; Table 4: Grading of Anterior Chamber Flare and Anterior Chamber Cells; Table 5: Grading of Vitreous Haze; Table 6: Autoimmune Uveitis and Ocular Complications; Table 7: Risk Factors and Comorbidities for Uveitis; Table 8: Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation, Etiology, and Severity; Table 9: Diagnosed Prevalent Cases of Uveitis by Laterality; Table 10: Treatment Guidelines for Uveitis in the 9MM; Table 11: Uveitis Disease Management - North America; Table 12: Uveitis Disease Management - 5EU; Table 13: Uveitis Disease Management - Japan and Australia; Table 14: Marketed Drugs for Uveitis Across the 9MM; Table 15: Comparison of Therapeutic Classes of Pipeline Drug Candidates for Non-infectious Uveitis, 2019-2029; Table 16: Phase I Pipeline Products in Development for Uveitis; Table 17: AbbVie’s Uveitis Portfolio Assessment, 2021; Table 18: Novartis’ Uveitis Portfolio Assessment, 2021; Table 19: Chugai’s Uveitis Portfolio Assessment, 2021; Table 20: Aciont’s Uveitis Portfolio Assessment, 2021; Table 21: Oculis’ Uveitis Portfolio Assessment, 2021; Table 22: Tarsius Pharma’s Uveitis Portfolio Assessment, 2021; Table 23: Enzo Biochem’s Uveitis Portfolio Assessment, 2021; Table 24: Santen’s Uveitis Portfolio Assessment, 2021; Table 25: Eyevensys’ Uveitis Portfolio Assessment, 2021; Table 26: Panoptes Pharma’s Uveitis Portfolio Assessment, 2021; Table 27: Uveitis Market - Global Drivers and Barriers, 2019-2029; Table 28: Key Events Impacting Sales for Uveitis in the US, 2019-2029; Table 29: Uveitis Market - Drivers and Barriers in the US, 2019-2029; Table 30: Key Events Impacting Sales for Uveitis in the 5EU, 2019-2029; Table 31: Uveitis Market - Drivers and Barriers in the 5EU, 2019-2029; Table 32: Key Events Impacting Sales for Uveitis in Japan, 2019-2029; Table 33: Uveitis Market - Drivers and Barriers in Japan, 2019-2029; Table 34: Key Events Impacting Sales for Uveitis in Canada, 2019-2029; Table 35: Uveitis Market - Drivers and Barriers in Canada, 2019-2029; Table 36: Key Events Impacting Sales for Uveitis in Australia, 2019-2029; Table 37: Uveitis Market - Drivers and Barriers in Australia, 2019-2029; Table 38: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures: Figure 1: Global (9MM) Sales Forecast by Geographic Region for Uveitis in 2019 and 2029; Figure 2: Analysis of the Company Portfolio Gap in Uveitis During the Forecast Period; Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Uveitis During the Forecast Period; Figure 4: Differentiation of Pro-inflammatory T-cells in Non-infectious Uveitis; Figure 5: 9MM, Diagnosed Incidence of Uveitis, Men and Women, Cases Per 100,000 Population, Ages ≥18 Years, 2019; Figure 6: 9MM, Diagnosed Prevalence of Uveitis, Men and Women, %, Ages ≥18 Years, 2019; Figure 7: 9MM, Sources Used and Not Used to Forecast the Diagnosed Incident and Diagnosed Prevalent Cases of Uveitis; Figure 8: 9MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation; Figure 9: 9MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Uveitis by Etiology; Figure 10: 9MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Uveitis by Severity; Figure 11: 9MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Uveitis by Laterality; Figure 12: 9MM, Diagnosed Incident Cases of Uveitis, N, Both Sexes, Ages ≥18 Years, 2019; Figure 13: 9MM, Diagnosed Incident Cases of Uveitis by Age, N, Both Sexes, 2019; Figure 14: 9MM, Diagnosed Incident Cases of Uveitis by Sex, N, Ages ≥18 Years, 2019; Figure 15: 9MM, Diagnosed Prevalent Cases of Uveitis, N, Both Sexes, Ages ≥18 Years, 2019; Figure 16: 9MM, Diagnosed Prevalent Cases of Uveitis by Age, N, Both Sexes, 2019; Figure 17: 9MM, Diagnosed Prevalent Cases of Uveitis by Sex, N, Ages ≥18 Years, 2019; Figure 18: Unmet Needs and Opportunities in Uveitis; Figure 19: Snellen Chart Used to Measure Visual Acuity in Patients With Uveitis; Figure 20: Overview of the Development Pipeline in Uveitis; Figure 21: Key Ongoing Clinical Trials Involving Patients With Non-infectious Uveitis in the 9MM; Figure 22: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Uveitis During the Forecast Period; Figure 23: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC Ocular Application, Pred Forte; Figure 24: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC Systemic Treatment, Humira; Figure 25: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC Intraocular Preparation, Ozurdex; Figure 26: Analysis of the Company Portfolio Gap in Uveitis During the Forecast Period; Figure 27: Global (9MM) Sales Forecast by Geographic Region for Uveitis in 2019 and 2029; Figure 28: Sales of Corticosteroids for Uveitis in the 9MM, 2019 and 2029; Figure 29: Sales Forecast by Therapeutic Class for Uveitis in the 9MM, 2019 and 2029; Figure 30: Sales Forecast by Therapeutic Class for Uveitis in the US in 2019 and 2029; Figure 31: Sales Forecast by Therapeutic Class for Uveitis in the 5EU in 2019 and 2029; Figure 32: Sales Forecast by Therapeutic Class for Uveitis in Japan in 2019 and 2029; Figure 33: Sales Forecast by Therapeutic Class for Uveitis in Canada in 2019 and 2029; Figure 34: Sales Forecast by Therapeutic Class for Uveitis in Australia in 2019 and 2029